Resistance mechanisms to methotrexate in tumors

Stem Cells

Volumn 14, Issue 1, 1996, Pages 5-9

  Bertino, J R ^a   Goker E ^a   Gorlick, R ^a   Li, W W ^a   Banerjee, D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Dihydrofolate reductase; Drug resistance; Folylpolyglutamate synthetase; Leukemia; Methotrexate; Sarcoma; Trimetrexate; glutamyl hydrolase

Indexed keywords

AMINOPTERIN; DIHYDROFOLATE REDUCTASE; FOLINIC ACID; FOLYLPOLYGLUTAMATE SYNTHASE; GAMMA GLUTAMYL HYDROLASE; METHOTREXATE; POLYGLUTAMIC ACID; RETINOBLASTOMA PROTEIN;

ACUTE LYMPHOCYTIC LEUKEMIA; DRUG MECHANISM; DRUG RETENTION; DRUG UPTAKE; ENZYME ACTIVITY; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; REVIEW; RNA TRANSLATION; SOFT TISSUE SARCOMA; TUMOR SUPPRESSOR GENE;

EID: 0030054105     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.140005     Document Type: Review

References (27)

1. Farber S, Diamond LK, Mercer RD et al. Temporary remissions in acute leukemia in children produced by folic acid antagonist. 4-aminopteroyl-glutamic acid (aminopterin). N Engl J Med 1948;238:787-793.
2. Li MC, Hertz R, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 1956;93:361-366.
3. Allegra CJ, Antifolates. In: Chabner BA, Collins JM, eds. Cancer Chemotherapy: Principles and Practice. Philadelphia: JB Lippincott, 1990:110-153.
4. Rhee MS, Wang Y, Nair MG et al. Acquisition of resistance to antifolates caused by enhanced γ-glutamyl hydrolase activity. Cancer Res 1993;53:2227-2230.
5. Schweitzer BI, Dicker AP, Bertino JR. Dihydrofolate reductase as a therapeutic target. FASEB J 1990;4:2441-2452.
6. Goldman ID, Matherly LH. The cellular pharmacology of methotrexate. In: Goldman ID, ed. Membrane Transport of Antineoplastic Agents (International Encyclopedia of Pharmacology and Therapeutics; Section 118). Oxford: Pergamon Press. 1986:241-281.
7. Sirotnak FM. Determinants of resistance to antifolates: biochemical phenotypes, their frequency of occurrence and circumvention. NCI Monographs 1986;5:27-35.
8. Dixon KH, Lanpher BC, Chiu J et al. A novel cDNA restores reduced folate carrier activity and methotrexate sensitivity to transport deficient cells. J Biol Chem 1994;269:17-20.
9. Williams FMR, Murray RC, Underhill TM et al. Isolation of a hamster cDNA clone coding for a function involved in methotrexate uptake. J Biol Chem 1994;269:5810-5816.
10. Trippett T, Schlemmer S, Elisseyeff Y et al. Defective transport as a mechanism of acquired resistance to methotrexate in patients with acute leukemia. Blood 1992;80:1158-1162.
11. Li WW, Lin JT, Tong WP et al. Mechanisms of natural and acquired resistance to antifolates in human soft tissue sarcomas. Cancer Res 1992;52:1434-1438.
12. Lin JT, Tong WP, Trippett TM et al. Basis for natural resistance to methotrexate in human acute non-lymphoblastic leukemia. Leukemia Res 1991;15:1191-1196.
13. Göker E, Kheradpour A, Waltham M et al. Acute monocytic leukemia: a myeloid subset that may be sensitive to methotrexate. Leukemia 1995;9:274-276.
14. Göker E, Lin JT, Trippett TM et al. Decreased polyglutamylation of methotrexate in acute lymphoblastic leukemia in adults as compared to children with this disease. Leukemia 1993;7:1000-1004.
15. Lenz HJ, Schnieders B, Danenberg K et al. A polymerase chain reaction (PCR) assay for folylpolyglutamate synthetase (FPGS) gene expression: marked variation in human leukemia blast samples. Proc Am Soc Can Res 1993;34:504a.
16. Schimke RT. Gene amplification in cultured cells. J Biol Chem 1988;263:5989-5992.
17. Göker E. Waltham M, Kheradpour A et al. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations. Blood 1995;86:677-684
18. Ercikan E, Banerjee D, Waltham M et al. Translational regulation of the synthesis of dihydrofolate reductase. In: Ayling JE, Nair MG, Baugh CM, eds. Chemistry and Biology of Pteridines and Folates Vol. 338. New York: Plenum Press. 1993:537-540.
19. Chu E, Takimoto CH, Voeller D et al. Specific binding of human dihydrofolate reductase protein to dihydrofolate reductase messenger RNA in vitro. Biochemistry 1993;32:4756-4760.
20. Li WW, Fan JG, Zielenski Z et al. Absence of retinoblastoma protein mediates intrinsic resistance to antimetabolites in sarcoma cell lines. Proc Natl Acad Sci USA. (in press).
21. Yin Y, Tainsky MA, Bischoff FZ et al. Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992;70:937-948.
22. Livingstone LR, White A, Sprouse J et al. Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Cell 1992;70:923-936.
23. Lin JT, Bertino JR. Trimetrexate: a second generation folate antagonist in clinical trial. J Clin Oncol 1987;5:2032-2040.
24. Kheradpour A, Barman E, Göker E et al. A phase II study of continuous infusion of trimetrexate in patients with refractory acute leukemia. Cancer Invest 1995;13:36-40.
25. Pappo A, Dubowy R, Ravindranata Y et al. Phase II trial of trimetrexate in the treatment of recurrent childhood acute lymphoblastic leukemia: Pediatric Oncology Group Study. J Natl Cancer Inst 1990;82:1641-1642.
26. Allegra CJ, Chabner BA, Tuazon CU et al. Trimetrexate for the treatment of pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. N Engl J Med 1987;317:978-985.
27. Lacerda JF, Göker E, Kheradpour A et al. Selective treatment of SCID mice bearing methotrexate-transport resistant human acute leukemia tumors with trimetrexate and leucovorin protection. Blood 1995;85:2675-2679.